Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Accumulated Expenses (2018 - 2023)

Marker Therapeutics (MRKR) has disclosed Accumulated Expenses for 7 consecutive years, with $610000.0 as the latest value for Q2 2023.

  • On a quarterly basis, Accumulated Expenses fell 61.02% to $610000.0 in Q2 2023 year-over-year; TTM through Jun 2023 was $610000.0, a 61.02% decrease, with the full-year FY2022 number at $750000.0, down 68.75% from a year prior.
  • Accumulated Expenses was $610000.0 for Q2 2023 at Marker Therapeutics, up from $454000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $2.4 million in Q3 2021 to a low of $323000.0 in Q4 2019.
  • A 5-year average of $1.2 million and a median of $858000.0 in 2020 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 424.46% in 2020, then tumbled 68.75% in 2022.
  • Marker Therapeutics' Accumulated Expenses stood at $323000.0 in 2019, then surged by 424.46% to $1.7 million in 2020, then soared by 41.68% to $2.4 million in 2021, then crashed by 68.75% to $750000.0 in 2022, then decreased by 18.67% to $610000.0 in 2023.
  • Per Business Quant, the three most recent readings for MRKR's Accumulated Expenses are $610000.0 (Q2 2023), $454000.0 (Q1 2023), and $750000.0 (Q4 2022).